Brown, B. K., Lombardi, K., Bryson, M., Currier, J., Thelian, D., Wieczorek, L., … Polonis, V. R. (2009). P04-12. Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assays. In Retrovirology (Vol. 6). https://doi.org/10.1186/1742-4690-6-S3-P40

Brown, B. K., K. Lombardi, M. Bryson, J. Currier, D. Thelian, L. Wieczorek, G. Kijak, et al. “P04-12. Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assays.” In Retrovirology, Vol. 6, 2009. https://doi.org/10.1186/1742-4690-6-S3-P40.

Brown BK, Lombardi K, Bryson M, Currier J, Thelian D, Wieczorek L, et al. P04-12. Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assays. In: Retrovirology. 2009.

Brown, B. K., et al. “P04-12. Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assays.” Retrovirology, vol. 6, no. SUPPL. 3, 2009. Scopus, doi:10.1186/1742-4690-6-S3-P40.

Brown BK, Lombardi K, Bryson M, Currier J, Thelian D, Wieczorek L, Kijak G, Kappes JC, Ochsenbauer-Jambor C, Michael NL, Montefiori D, Polonis VR. P04-12. Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assays. Retrovirology. 2009.